S. 4395 is a bill intended to reauthorize the Terrorism Risk Insurance Act (TRIA) of 2002. The original TRIA was established to create a federal backstop for insurance claims related to acts of terrorism, ensuring that insurance companies can cover such claims without risking financial instability. This reauthorization likely extends the provisions of the original act, possibly updating or amending certain aspects to address current concerns and economic conditions.
Media coverage that supports S. 4395 often highlights the bill's role in maintaining stability in the insurance market by providing a safety net for terrorism-related claims. Proponents argue that reauthorizing TRIA is crucial for protecting businesses and the economy from the potentially devastating financial impacts of terrorist attacks. Supporters also emphasize the importance of government involvement in mitigating risks that private insurers may be unable or unwilling to cover alone.
Criticism of S. 4395 in the media may focus on the perceived over-reliance on government intervention in the insurance industry. Opponents might argue that the bill could lead to increased government spending and question the necessity of reauthorization given the evolving nature of terrorism threats. Some critics might also suggest that the private sector should develop more robust mechanisms to handle such risks without federal support.
Based on the available data, the risk of conflicts of interest between the sponsor's donors and the bill's subject matter appears to be low. There are no direct overlaps detected between the bill subjects and sponsor's top donor industries. However, there is significant lobbying activity in the bill's policy area, with several entities having paid for lobbying services. The highest lobbying amount comes from BAE, Kim & Lee, LLC, which spent $370,000 via The McKeon Group, Inc. Other notable amounts include $150,000 from MBK Partners and $70,000 from B. Braun Medical Inc. Despite these amounts, there is no direct evidence of a conflict of interest as none of these entities are among the sponsor's top donors. It is important for voters to be aware of these financial dynamics, but at this stage, there is no clear indication of a conflict of interest.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| BAE, KIM & LEE, LLC | THE MCKEON GROUP, INC. | $370,000 |
| MBK PARTNERS | THE MCKEON GROUP, INC. | $150,000 |
| B. BRAUN MEDICAL INC. | POLSINELLI PC | $70,000 |
| VECTOR | THE MCKEON GROUP, INC. | $40,000 |
| SOLUTION PHILIPPINES, LLC | THE MCKEON GROUP, INC. | $40,000 |
| AMERICAN PHARMACISTS ASSOCIATION | AMERICAN PHARMACISTS ASSOCIATION | $35,000 |
| D-WAVE GOVERNMENT, INC | THE MCKEON GROUP, INC. | $10,000 |
| NATIONAL ASSOCIATION OF RSVP PROGRAM DIRECTORS | THE SUSQUEHANNA GROUP | $5,000 |
| STR8 CORPORATION | BRODY GROUP L.L.C. PUBLIC AFFAIRS | undisclosed |
| WEST GULF MARITIME ASSOCIATION | WEST GULF MARITIME ASSOCIATION | undisclosed |
| CENTRAL ADMIXTURE PHARMACY SERVICES, INC. | POLSINELLI PC | undisclosed |
| CARTRIDGE TECHNOLOGIES, LLC | CHECKMATE GOVERNMENT RELATIONS | undisclosed |
| BLUE DIAMOND ATOMICS | NATURAL STATE CONSULTING AND STRATEGIES | undisclosed |
| POPLICUS INCORPORATED DBA GOVINI | CHECKMATE GOVERNMENT RELATIONS | undisclosed |
| STRYDENT AUTONOMOUS TECHNOLOGIES | POTOMAC STRATEGIC CONSULTING LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding Dave McCormick, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
